...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
【24h】

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

机译：治疗后十二周的随访与24周的随访有关，以确定接受聚乙二醇化干扰素和利巴韦林的丙型肝炎病毒患者的持续病毒学应答。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A sustained virologic response (SVR) in patients with chronic hepatitis C receiving pegylated interferon (PEG-IFN) plus ribavirin is defined as undetectable serum HCV-RNA at 24 weeks (W+24) posttreatment follow-up. Viral load outcome in patients with virological relapse (VR) has not been explored. This study evaluated whether the assessment of serum HCV-RNA 12 weeks (W+12) after the end of treatment was as relevant as W+24 to evaluate SVR in 573 patients who received combination PEG-IFN and ribavirin and had a virological response at the end of treatment. Serum HCV-RNA was measured, using a new assay based on transcription-mediated amplification (TMA) with a lowest detection limit of 5-10 IU/mL, at W+12 and W+24 after the end of treatment. VR was defined as reappearance of detectable HCV-RNA at W+24 posttreatment follow-up. The positive predictive value (PPV) of undetectable serum HCV-RNA at W+12 was evaluated to identify patients with SVR, and the viral load outcome was measured in relapse patients. At the W+24 posttreatment follow-up, 408 (71%) patients had an SVR, 181 (71.2%) were treated with PEG-IFNalpha-2a and ribavirin, and 227 (71.1%) were treated with PEG-IFNalpha-2b and ribavirin. At W+12, serum HCV-RNA was undetectable in 409 patients, and 408 patients were SVR (PPV 99.7%, 95% confidence interval 99.1-100). In relapse patients, serum HCV-RNA levels were 5.623 +/- 0.748, 4.979 +/- 0.870, and 5.216 +/- 0.758 log(10) IU/mL at baseline, W+12, and W+24, respectively. Conclusion: Our results show that the assessment of serum HCV-RNA 12 weeks after the end of treatment, using the highly sensitive TMA assay (PPV 99.7%), is as relevant as after 24 weeks to predict SVR and make decisions on the management of treated patients, suggesting a new definition for SVR.
机译：接受聚乙二醇干扰素（PEG-IFN）加利巴韦林治疗的慢性丙型肝炎患者的持续病毒学应答（SVR）被定义为治疗后24周（W + 24）不能检测到的血清HCV-RNA。尚未探讨病毒学复发（VR）患者的病毒载量结果。这项研究评估了治疗结束后12周（W + 12）血清HCV-RNA的评估是否与W + 24评估在573例接受PEG-IFN和利巴韦林联用并在2012年有病毒学应答的患者中的SVR相关性治疗结束。在治疗结束后的W + 12和W + 24，使用基于转录介导扩增（TMA）的新测定法测定血清HCV-RNA，最低检出限为5-10 IU / mL。 VR被定义为在治疗后W + 24时可检测到的HCV-RNA再次出现。评价在W + 12时检测不到的血清HCV-RNA的阳性预测值（PPV）以鉴定SVR患者，并测量复发患者的病毒载量结果。在W + 24治疗后的随访中，有408名患者（71％）患有SVR，181名（71.2％）患者接受了PEG-IFNalpha-2a和利巴韦林的治疗，227名（71.1％）患者接受了PEG-IFNalpha-2b的治疗。和利巴韦林。在W + 12，有409例患者未检测到血清HCV-RNA，有408例患者为SVR（PPV为99.7％，95％置信区间为99.1-100）。在复发患者中，血清HCV-RNA水平在基线，W + 12和W + 24分别为5.623 +/- 0.748、4.979 +/- 0.870和5.216 +/- 0.758 log（10）IU / mL。结论：我们的结果表明，在治疗结束后12周使用高灵敏度TMA分析（PPV 99.7％）评估血清HCV-RNA与24周后预测SVR并做出治疗决策相关性高。治疗的患者，为SVR提出了新的定义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号